James Richardson
Analyst
Equibles does not estimate personal net worth.
About James Richardson
James Richardson has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Sarepta Therapeutics, Inc. on September 14, 2026. The companies whose calls James Richardson spoke on are classified in the Healthcare sector.
James Richardson on recent calls
“So, I mean, what we showed were the Ducks 4G regulated panels.”
“I mean, I think you've covered it really, Louise. FSHD is a slowly progressive disease. We expect the treatment here to improve symptoms. We expect it to stabilize the disease, similar paradigm to DMD, and we need time for the disease to progress to show the therapeutic effects of stabilization.”